Districts (or national) Bronx
Date
Title
Status
All
Completed
Current
Soon to Launch
Program Affiliation
All
HPTN
MTCT-Plus
CTU
COVID
MCAP
UTAP
Global TA
PHIA
QICIP
TRACE
CQUIN
GNCBP
OpCon
OPTIMIZE
Project Location
All
Mozambique
Angola
Senegal
Panama
Honduras
El Salvador
Harlem
Bronx
Burundi
Liberia
Colombia & Peru
Philippines
Brazil
Guatemala
Georgia
Haiti
China
Cameroon
Côte d’Ivoire
Democratic Republic of the Congo
Lesotho
Kazakhstan
Kyrgyzstan
Kenya
Namibia
Ethiopia
Nigeria
Rwanda
Tajikistan
Malawi
Sierra Leone
Zimbabwe
Tanzania
Eswatini
South Sudan
Mali
South Africa
Uganda
Zambia
United States
Ukraine
Myanmar
Central Asia
may
Project Details
This study examined the drug levels of the antiretroviral agent tenofovir in rectal tissue after it has been used as a gel in the vagina and vice versa. (funded by
Project Details
Project Details
This study investigated the experimental microbicide gel tenofovir to protect women against HIV. The study provided information on how much vaginal tenofovir gel, when used in combination with common vaginal
Project Details
HTPN 083: Give PrEP a ShotDistricts (or national):Bronx
Project Details
HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB
Project Details
Closed to enrollment, in active study follow-up
Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094 https://www.hptn.org/research/studies/hptn083 https://giveprepashot.org/
HVTN 704/HPTN 085: Antibody Mediated Prevention (Amp Study)Districts (or national):Bronx
Project Details
HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study testing the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV. The
Project Details
Project Details
HPTN 076 was a two-year study that recruited sexually active women age 18 to 45 and evaluated the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for
Project Details
HPTN 094: The INTEGRA StudyDistricts (or national):Bronx
Project Details
A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and
Project Details
Soon to begin enrollment
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190
CoVPN 3002: The AstraZeneca StudyDistricts (or national):Bronx
Project Details
This randomized, double-blind, placebo-controlled multicenter s investigates the AstraZeneca (AZD1222) vaccine to prevent COVID-19 Closed to enrollment, follow up ongoing Web Links: https://clinicaltrials.gov/ct2/show/NCT04516746
Project Details
Closed to enrollment, follow up ongoing
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04516746
CoVPN 5002: The COMPASS StudyDistricts (or national):Bronx
Project Details
The SARS-COV-2 prevalence study is to assess the prevalence of active and recovered COVID infections in the Bronx community Open to enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04658121 https://www.compassstudy.org/
Project Details
IMPOWER-022: The Merck Study (on hold)Districts (or national):Bronx
Project Details
A randomized, active-controlled, double-blind clinical study to investigate the safety and efficacy of oral Islatravir, a once-monthly pill as preexposure prophylaxis (PrEP) in cisgender women at high risk for HIV-1
Project Details
EVOGUARD/EVO100-311: The ICON StudyDistricts (or national):Bronx
Project Details
A randomized, placebo-controlled efficacy trial of EVO100 vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhoeae infection in sexually active young women who have recently had Chlamydia or
Project Details
ACTIV-2/A5401: The ACTIV StudyDistricts (or national):Bronx
Project Details
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID). This multicenter study aims to rapidly identify safe and effective treatments for COVID-19. Ambulatory adults who have recently been
Project Details
Soon to begin enrollment
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04885530
Making PrEP SmartDistricts (or national):Bronx
Project Details
The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month
Project Details
june
Project Details
This study examined the drug levels of the antiretroviral agent tenofovir in rectal tissue after it has been used as a gel in the vagina and vice versa. (funded by
Project Details
Project Details
This study investigated the experimental microbicide gel tenofovir to protect women against HIV. The study provided information on how much vaginal tenofovir gel, when used in combination with common vaginal
Project Details
HTPN 083: Give PrEP a ShotDistricts (or national):Bronx
Project Details
HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB
Project Details
Closed to enrollment, in active study follow-up
Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094 https://www.hptn.org/research/studies/hptn083 https://giveprepashot.org/
HVTN 704/HPTN 085: Antibody Mediated Prevention (Amp Study)Districts (or national):Bronx
Project Details
HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study testing the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV. The
Project Details
Project Details
HPTN 076 was a two-year study that recruited sexually active women age 18 to 45 and evaluated the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for
Project Details
HPTN 094: The INTEGRA StudyDistricts (or national):Bronx
Project Details
A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and
Project Details
Soon to begin enrollment
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190
CoVPN 3002: The AstraZeneca StudyDistricts (or national):Bronx
Project Details
This randomized, double-blind, placebo-controlled multicenter s investigates the AstraZeneca (AZD1222) vaccine to prevent COVID-19 Closed to enrollment, follow up ongoing Web Links: https://clinicaltrials.gov/ct2/show/NCT04516746
Project Details
Closed to enrollment, follow up ongoing
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04516746
CoVPN 5002: The COMPASS StudyDistricts (or national):Bronx
Project Details
The SARS-COV-2 prevalence study is to assess the prevalence of active and recovered COVID infections in the Bronx community Open to enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04658121 https://www.compassstudy.org/
Project Details
IMPOWER-022: The Merck Study (on hold)Districts (or national):Bronx
Project Details
A randomized, active-controlled, double-blind clinical study to investigate the safety and efficacy of oral Islatravir, a once-monthly pill as preexposure prophylaxis (PrEP) in cisgender women at high risk for HIV-1
Project Details
EVOGUARD/EVO100-311: The ICON StudyDistricts (or national):Bronx
Project Details
A randomized, placebo-controlled efficacy trial of EVO100 vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhoeae infection in sexually active young women who have recently had Chlamydia or
Project Details
ACTIV-2/A5401: The ACTIV StudyDistricts (or national):Bronx
Project Details
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID). This multicenter study aims to rapidly identify safe and effective treatments for COVID-19. Ambulatory adults who have recently been
Project Details
Soon to begin enrollment
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04885530
Making PrEP SmartDistricts (or national):Bronx
Project Details
The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month
Project Details
july
Project Details
This study examined the drug levels of the antiretroviral agent tenofovir in rectal tissue after it has been used as a gel in the vagina and vice versa. (funded by
Project Details
Project Details
This study investigated the experimental microbicide gel tenofovir to protect women against HIV. The study provided information on how much vaginal tenofovir gel, when used in combination with common vaginal
Project Details
HTPN 083: Give PrEP a ShotDistricts (or national):Bronx
Project Details
HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB
Project Details
Closed to enrollment, in active study follow-up
Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094 https://www.hptn.org/research/studies/hptn083 https://giveprepashot.org/
HVTN 704/HPTN 085: Antibody Mediated Prevention (Amp Study)Districts (or national):Bronx
Project Details
HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study testing the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV. The
Project Details
Project Details
HPTN 076 was a two-year study that recruited sexually active women age 18 to 45 and evaluated the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for
Project Details
HPTN 094: The INTEGRA StudyDistricts (or national):Bronx
Project Details
A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and
Project Details
Soon to begin enrollment
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190
CoVPN 3002: The AstraZeneca StudyDistricts (or national):Bronx
Project Details
This randomized, double-blind, placebo-controlled multicenter s investigates the AstraZeneca (AZD1222) vaccine to prevent COVID-19 Closed to enrollment, follow up ongoing Web Links: https://clinicaltrials.gov/ct2/show/NCT04516746
Project Details
Closed to enrollment, follow up ongoing
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04516746
CoVPN 5002: The COMPASS StudyDistricts (or national):Bronx
Project Details
The SARS-COV-2 prevalence study is to assess the prevalence of active and recovered COVID infections in the Bronx community Open to enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04658121 https://www.compassstudy.org/
Project Details
IMPOWER-022: The Merck Study (on hold)Districts (or national):Bronx
Project Details
A randomized, active-controlled, double-blind clinical study to investigate the safety and efficacy of oral Islatravir, a once-monthly pill as preexposure prophylaxis (PrEP) in cisgender women at high risk for HIV-1
Project Details
EVOGUARD/EVO100-311: The ICON StudyDistricts (or national):Bronx
Project Details
A randomized, placebo-controlled efficacy trial of EVO100 vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhoeae infection in sexually active young women who have recently had Chlamydia or
Project Details
ACTIV-2/A5401: The ACTIV StudyDistricts (or national):Bronx
Project Details
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID). This multicenter study aims to rapidly identify safe and effective treatments for COVID-19. Ambulatory adults who have recently been
Project Details
Soon to begin enrollment
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04885530
Making PrEP SmartDistricts (or national):Bronx
Project Details
The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month
Project Details
august
Project Details
This study examined the drug levels of the antiretroviral agent tenofovir in rectal tissue after it has been used as a gel in the vagina and vice versa. (funded by
Project Details
Project Details
This study investigated the experimental microbicide gel tenofovir to protect women against HIV. The study provided information on how much vaginal tenofovir gel, when used in combination with common vaginal
Project Details
HTPN 083: Give PrEP a ShotDistricts (or national):Bronx
Project Details
HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB
Project Details
Closed to enrollment, in active study follow-up
Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094 https://www.hptn.org/research/studies/hptn083 https://giveprepashot.org/
HVTN 704/HPTN 085: Antibody Mediated Prevention (Amp Study)Districts (or national):Bronx
Project Details
HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study testing the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV. The
Project Details
Project Details
HPTN 076 was a two-year study that recruited sexually active women age 18 to 45 and evaluated the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for
Project Details
HPTN 094: The INTEGRA StudyDistricts (or national):Bronx
Project Details
A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and
Project Details
Soon to begin enrollment
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190
CoVPN 3002: The AstraZeneca StudyDistricts (or national):Bronx
Project Details
This randomized, double-blind, placebo-controlled multicenter s investigates the AstraZeneca (AZD1222) vaccine to prevent COVID-19 Closed to enrollment, follow up ongoing Web Links: https://clinicaltrials.gov/ct2/show/NCT04516746
Project Details
Closed to enrollment, follow up ongoing
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04516746
CoVPN 5002: The COMPASS StudyDistricts (or national):Bronx
Project Details
The SARS-COV-2 prevalence study is to assess the prevalence of active and recovered COVID infections in the Bronx community Open to enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04658121 https://www.compassstudy.org/
Project Details
IMPOWER-022: The Merck Study (on hold)Districts (or national):Bronx
Project Details
A randomized, active-controlled, double-blind clinical study to investigate the safety and efficacy of oral Islatravir, a once-monthly pill as preexposure prophylaxis (PrEP) in cisgender women at high risk for HIV-1
Project Details
EVOGUARD/EVO100-311: The ICON StudyDistricts (or national):Bronx
Project Details
A randomized, placebo-controlled efficacy trial of EVO100 vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhoeae infection in sexually active young women who have recently had Chlamydia or
Project Details
ACTIV-2/A5401: The ACTIV StudyDistricts (or national):Bronx
Project Details
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID). This multicenter study aims to rapidly identify safe and effective treatments for COVID-19. Ambulatory adults who have recently been
Project Details
Soon to begin enrollment
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04885530
Making PrEP SmartDistricts (or national):Bronx
Project Details
The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month
Project Details
september
Project Details
This study examined the drug levels of the antiretroviral agent tenofovir in rectal tissue after it has been used as a gel in the vagina and vice versa. (funded by
Project Details
Project Details
This study investigated the experimental microbicide gel tenofovir to protect women against HIV. The study provided information on how much vaginal tenofovir gel, when used in combination with common vaginal
Project Details
HTPN 083: Give PrEP a ShotDistricts (or national):Bronx
Project Details
HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB
Project Details
Closed to enrollment, in active study follow-up
Web Links:
https://clinicaltrials.gov/ct2/show/NCT02720094 https://www.hptn.org/research/studies/hptn083 https://giveprepashot.org/
HVTN 704/HPTN 085: Antibody Mediated Prevention (Amp Study)Districts (or national):Bronx
Project Details
HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study testing the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV. The
Project Details
Project Details
HPTN 076 was a two-year study that recruited sexually active women age 18 to 45 and evaluated the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for
Project Details
HPTN 094: The INTEGRA StudyDistricts (or national):Bronx
Project Details
A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and
Project Details
Soon to begin enrollment
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04804072 https://www.hptn.org/research/studies/190
CoVPN 3002: The AstraZeneca StudyDistricts (or national):Bronx
Project Details
This randomized, double-blind, placebo-controlled multicenter s investigates the AstraZeneca (AZD1222) vaccine to prevent COVID-19 Closed to enrollment, follow up ongoing Web Links: https://clinicaltrials.gov/ct2/show/NCT04516746
Project Details
Closed to enrollment, follow up ongoing
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04516746
CoVPN 5002: The COMPASS StudyDistricts (or national):Bronx
Project Details
The SARS-COV-2 prevalence study is to assess the prevalence of active and recovered COVID infections in the Bronx community Open to enrollment Web Links: https://clinicaltrials.gov/ct2/show/NCT04658121 https://www.compassstudy.org/
Project Details
IMPOWER-022: The Merck Study (on hold)Districts (or national):Bronx
Project Details
A randomized, active-controlled, double-blind clinical study to investigate the safety and efficacy of oral Islatravir, a once-monthly pill as preexposure prophylaxis (PrEP) in cisgender women at high risk for HIV-1
Project Details
EVOGUARD/EVO100-311: The ICON StudyDistricts (or national):Bronx
Project Details
A randomized, placebo-controlled efficacy trial of EVO100 vaginal gel for the prevention of Chlamydia trachomatis and Neisseria gonorrhoeae infection in sexually active young women who have recently had Chlamydia or
Project Details
ACTIV-2/A5401: The ACTIV StudyDistricts (or national):Bronx
Project Details
Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID). This multicenter study aims to rapidly identify safe and effective treatments for COVID-19. Ambulatory adults who have recently been
Project Details
Soon to begin enrollment
Web Links:
https://clinicaltrials.gov/ct2/show/NCT04885530
Making PrEP SmartDistricts (or national):Bronx
Project Details
The purpose of this study is to understand if a smartphone app, SmartPrEP, will help promote HIV self testing and PrEP adherence among cisgender and transgender women over a twelve-month